Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-drug Conjugate Targeting PSMA, in Pre-clinical Models of Prostate Cancer

Cho, S; Zammarchi, F; Williams, DG; Havenith, CE; Monks, NR; Tyrer, P; d'Hooge, F; ... van Berkel, PH; + view all Cho, S; Zammarchi, F; Williams, DG; Havenith, CE; Monks, NR; Tyrer, P; d'Hooge, F; Fleming, R; Vashisht, K; Dimasi, N; Bertelli, F; Corbett, S; Adams, L; Reinert, HW; Dissanayake, S; Britten, CE; King, W; Dacosta, K; Tammali, R; Schifferli, K; Strout, P; Korade, M; Masson Hinrichs, MJ; Chivers, S; Corey, E; Liu, H; Kim, S; Bander, NH; Howard, PW; Hartley, JA; Coats, S; Tice, DA; Herbst, R; van Berkel, PH; - view fewer (2018) Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-drug Conjugate Targeting PSMA, in Pre-clinical Models of Prostate Cancer. Molecular Cancer Therapeutics 10.1158/1535-7163.MCT-17-0982 . (In press).

https://ift.tt/2Omznmu